Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J., Wierda, W. G., Zhao, W., Heerema, N. A., Luan, Y., Liu, E. A., Dean, J. P., O'Brien, S. M. AMER SOC HEMATOLOGY. 2018

View details for DOI 10.1182/blood-2018-99-110847

View details for Web of Science ID 000454842800284